Figure 1.
Figure 2.
Figure 3.
Figure 4.
Figure 5.
Figure 6.
The NOS for assessing the quality of studies in meta-analyses_
| Studies | Selection | Comparability | Outcome | Total score | |||||
|---|---|---|---|---|---|---|---|---|---|
| Author, year | Selection of cases | Selection of controls | Ascertainment of exposure | Outcome not present at the start | Comparability of cases and controls | Assessment of outcome | Follow-up duration | Follow-up % | |
| Mahmood et al. (15) | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 6 |
| Perl et al. (5) | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 6 |
| Irugulapati et al. (8)* | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 5 |
| Parks et al. (24)* | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 5 |
| Salguero et al. (23)* | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 5 |
| Sisniega et al. (22)* | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 7 |
| Abouzgheib et al. (21) | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 6 |
| Zalt et al. (20) | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 6 |
| Dammert et al. (19) | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 6 |
| Puchalski 2013 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 6 |
| Patel et al. (4) | 1 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 5 |
| Aljundi et al. (16) | 1 | 1 | 1 | 0 | 2 | 1 | 1 | 1 | 8 |
Baseline characteristics of included studies_
| Study | Design | Mean age | Participants/procedures | Male (%) | USG% | Concurrent aspirin (%) | Renal disease (%) | Procedure type | Drug studied |
|---|---|---|---|---|---|---|---|---|---|
| Mahmood et al. (15) | Prospective | 70.2 ± 13.3 | 25 | 21 (84) | 100 | 22 (88) | 3 (12) | TC + SBCT | Clopidogrel |
| Perl et al. (5) | Retrospective | 77.5 ± 11 | 88 | 53 (60) | 25 | 41 (46) | 26 (29.5) | TC | Clopidogrel |
| Irugulapati et al. (8)* | Retrospective | N/A | 7 | N/A | N/A | N/A | 5 (71.4) | TC | Clopidogrel |
| Parks et al. (24)* | Retrospective | 65 (41–86) | 14 | 5 (35.6) | N/A | N/A | N/A | TC | Clopidogrel |
| Salguero et al. (23)* | Retrospective | N/A | 22 | N/A | 100 | 20 (91) | N/A | TC | Clopidogrel + Ticagrelor |
| Sisniega et al. (22)* | Retrospective | N/A | 5 | N/A | N/A | 2 (40) | N/A | IPC | Clopidogrel + Prasugrel |
| Abouzgheib et al. (21) | Retrospective | 73.1 | 24 | 8 (44.4) | 100 | 13 (72.2) | N/A | SBCT | Clopidogrel |
| Zalt et al. (20) | Prospective | 75.5 (41–96) | 45 | 9 (30) | 100 | N/A | N/A | TC | Clopidogrel |
| Dammert et al. (19) | Retrospective | 71 ± 10 | 43 | 21 (70) | 100 | 27 (91) | 4 (15) | SBCT | Clopidogrel |
| Puchalski et al. (18) | Prospective | N/A | 18 | N/A | 100 | N/A | N/A | TC | Clopidogrel |
| Patel et al. (17) | Retrospective | N/A | 72 | N/A | 100 | 58 (80) | N/A | TC | Clopidogrel + Ticagrelor |
| Aljundi et al. (16) | Retrospective | N/A | 32 | N/A | N/A | N/A | N/A | TC | Clopidogrel + Ticagrelor + Prasugrel |